{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:34:41Z","timestamp":1790505281734,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Identification of endogenous pathological amyloid \u03b2 peptides (A\u03b2) forms in the brains of patients with Alzheimer\u2019s disease (AD) is still unclear. In healthy brain, A\u03b2 can associate with Apolipoprotein E (ApoE) which is involved in its metabolism and clearance. In the brain of patients with AD, ApoE is cleaved and produces ApoE fragments. We studied the forms of A\u03b2 and their interaction with the ApoE fragments in post-mortem brains from control and AD patients by western blots and co-immunoprecipitation. Three A\u03b2-containing peptides and three ApoE fragments were specifically found in the brain of AD patients. Co-immunoprecipitations showed that ApoE fragments and A\u03b21\u201342 peptides are co-partners in heteromers of 18 and 16\u2009kDa while ApoE-fragments and A\u03b2 peptides of 12\u2009kDa did not interact with each other. Formation of the 18\u2009kDa ApoE-fragment\/A\u03b2 heteromers is specifically increased in ApoE4 carriers and is a strong brain marker of AD while 16\u2009kDa ApoE-fragment\/A\u03b2 and A\u03b2 12\u2009kDa correlate to memory deficit. These data show that in patients with AD, ApoE fragmentation generates peptides that trap A\u03b2 in the brain. Inhibiting the fragmentation or targeting ApoE fragments could be exploited to define strategies to detect or reverse AD.<\/jats:p>","DOI":"10.1038\/s41598-019-40438-4","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T11:03:45Z","timestamp":1552043025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["ApoE-fragment\/A\u03b2 heteromers in the brain of patients with Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Amandine","family":"Mouchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Charlotte","family":"Boutonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mazzocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Biendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Macrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Neuro-CEB Neuropathology Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"40438_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO. Molecular Medicine 8, 595\u2013608, https:\/\/doi.org\/10.15252\/emmm.201606210 (2016).","journal-title":"Molecular Medicine"},{"key":"40438_CR2","doi-asserted-by":"publisher","first-page":"31894","DOI":"10.1074\/jbc.271.50.31894","volume":"271","author":"R Wang","year":"1996","unstructured":"Wang, R., Sweeney, D., Gandy, S. E. & Sisodia, S. S. The Profile of Soluble Amyloid \u03b2 Protein in Cultured Cell Media: Detection and quantification of amyloid \u03b2 protein and variants by immunoprecipitation-mass spectrometry. Journal of Biological Chemistry 271, 31894\u201331902, https:\/\/doi.org\/10.1074\/jbc.271.50.31894 (1996).","journal-title":"Journal of Biological Chemistry"},{"key":"40438_CR3","doi-asserted-by":"publisher","first-page":"34186","DOI":"10.1074\/jbc.M501694200","volume":"280","author":"A Piccini","year":"2005","unstructured":"Piccini, A. et al. beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280, 34186\u201334192, https:\/\/doi.org\/10.1074\/jbc.M501694200 (2005).","journal-title":"J Biol Chem"},{"key":"40438_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00401-010-0690-1","volume":"120","author":"E Portelius","year":"2010","unstructured":"Portelius, E. et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer\u2019s disease. Acta neuropathologica 120, 185\u2013193, https:\/\/doi.org\/10.1007\/s00401-010-0690-1 (2010).","journal-title":"Acta neuropathologica"},{"key":"40438_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12952-017-0066-3","volume":"16","author":"S Hunter","year":"2017","unstructured":"Hunter, S. & Brayne, C. Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research? Journal of Negative Results in Biomedicine 16, 1, https:\/\/doi.org\/10.1186\/s12952-017-0066-3 (2017).","journal-title":"Journal of Negative Results in Biomedicine"},{"key":"40438_CR6","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1074\/jbc.M115.655183","volume":"291","author":"AP Gunn","year":"2016","unstructured":"Gunn, A. P. et al. Amyloid-\u03b2 Peptide A\u03b23pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. Journal of Biological Chemistry 291, 6134\u20136145, https:\/\/doi.org\/10.1074\/jbc.M115.655183 (2016).","journal-title":"Journal of Biological Chemistry"},{"key":"40438_CR7","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1074\/jbc.R118.003999","volume":"293","author":"J Dunys","year":"2018","unstructured":"Dunys, J., Valverde, A. & Checler, F. Are N- and C-terminally truncated A\u03b2 species key pathological triggers in Alzheimer\u2019s disease? Journal of Biological Chemistry 293, 15419\u201315428, https:\/\/doi.org\/10.1074\/jbc.R118.003999 (2018).","journal-title":"Journal of Biological Chemistry"},{"key":"40438_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat Neurosci 15, 349\u2013357, https:\/\/doi.org\/10.1038\/nn.3028 (2012).","journal-title":"Nat Neurosci"},{"key":"40438_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/awt062","volume":"136","author":"SE Lesn\u00e9","year":"2013","unstructured":"Lesn\u00e9, S. E. et al. Brain amyloid-\u03b2 oligomers in ageing and Alzheimer\u2019s disease. Brain 136, 1383\u20131398, https:\/\/doi.org\/10.1093\/brain\/awt062 (2013).","journal-title":"Brain"},{"key":"40438_CR10","unstructured":"Shankar, G. M. et al. Amyloid-[beta] protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med 14, 837\u2013842, http:\/\/www.nature.com\/nm\/journal\/v14\/n8\/suppinfo\/nm1782_S1.html (2008)."},{"key":"40438_CR11","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.1834302100","volume":"100","author":"Y Gong","year":"2003","unstructured":"Gong, Y. et al. Alzheimer\u2019s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 100, 10417\u201310422, https:\/\/doi.org\/10.1073\/pnas.1834302100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"40438_CR12","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/hmg\/ddr139","volume":"20","author":"M Manczak","year":"2011","unstructured":"Manczak, M., Calkins, M. J. & Reddy, P. H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer\u2019s disease: implications for neuronal damage. Human molecular genetics 20, 2495\u20132509, https:\/\/doi.org\/10.1093\/hmg\/ddr139 (2011).","journal-title":"Human molecular genetics"},{"issue":"825","key":"40438_CR13","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/j.neurobiolaging.2011.05.003","volume":"33","author":"F Bao","year":"2012","unstructured":"Bao, F. et al. Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 33(825), e821\u2013813, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.05.003 (2012).","journal-title":"Neurobiol Aging"},{"key":"40438_CR14","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1111\/j.1742-4658.2010.07719.x","volume":"277","author":"E Pham","year":"2010","unstructured":"Pham, E. et al. Progressive accumulation of amyloid-\u03b2 oligomers in Alzheimer\u2019s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS Journal 277, 3051\u20133067, https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07719.x (2010).","journal-title":"FEBS Journal"},{"key":"40438_CR15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2147\/ndt.s84266","volume":"11","author":"VV Giau","year":"2015","unstructured":"Giau, V. V., Bagyinszky, E., An, S. S. A. & Kim, S. Y. Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatric Disease and Treatment 11, 1723\u20131737, https:\/\/doi.org\/10.2147\/ndt.s84266 (2015).","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"40438_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-160169","volume":"53","author":"F El Gaamouch","year":"2016","unstructured":"El Gaamouch, F., Jing, P., Xia, J. & Cai, D. Alzheimer\u2019s Disease Risk Genes and Lipid Regulators. Journal of Alzheimer\u2019s disease: JAD 53, 15\u201329, https:\/\/doi.org\/10.3233\/JAD-160169 (2016).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"40438_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim, J., Basak, J. M. & Holtzman, D. M. The Role of Apolipoprotein E in Alzheimer\u2019s Disease. Neuron 63, 287\u2013303, https:\/\/doi.org\/10.1016\/j.neuron.2009.06.026 (2009).","journal-title":"Neuron"},{"key":"40438_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","volume":"10","author":"PB Verghese","year":"2011","unstructured":"Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer\u2019s disease and other neurological disorders. The Lancet Neurology 10, 241\u2013252, https:\/\/doi.org\/10.1016\/S1474-4422(10)70325-2 (2011).","journal-title":"The Lancet Neurology"},{"key":"40438_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo, T., Xu, H. & Bu, G. ApoE and A\u03b2 in Alzheimer\u2019s Disease: Accidental Encounters or Partners? Neuron 81, 740\u2013754, https:\/\/doi.org\/10.1016\/j.neuron.2014.01.045 (2014).","journal-title":"Neuron"},{"key":"40438_CR20","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.1523\/jneurosci.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto, T. et al. Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid \u03b2 Peptide. The Journal of Neuroscience 32, 15181\u201315192, https:\/\/doi.org\/10.1523\/jneurosci.1542-12.2012 (2012).","journal-title":"The Journal of Neuroscience"},{"key":"40438_CR21","doi-asserted-by":"publisher","first-page":"e14586","DOI":"10.1371\/journal.pone.0014586","volume":"6","author":"PB Jones","year":"2011","unstructured":"Jones, P. B. et al. Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-\u03b2 in Human Alzheimer Brain. PloS one 6, e14586, https:\/\/doi.org\/10.1371\/journal.pone.0014586 (2011).","journal-title":"PloS one"},{"key":"40438_CR22","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese, P. B. et al. ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions. Proceedings of the National Academy of Sciences 110, E1807\u2013E1816, https:\/\/doi.org\/10.1073\/pnas.1220484110 (2013).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"40438_CR23","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences 90, 1977\u20131981, https:\/\/doi.org\/10.1073\/pnas.90.5.1977 (1993).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"40438_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"E Corder","year":"1993","unstructured":"Corder, E. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261, 921\u2013923, https:\/\/doi.org\/10.1126\/science.8346443 (1993).","journal-title":"Science"},{"key":"40438_CR25","doi-asserted-by":"publisher","unstructured":"Tai, L. M. et al. EFAD Transgenic Mice as a Human APOE Relevant Preclinical Model of Alzheimer\u2019s Disease. Journal of lipid research, https:\/\/doi.org\/10.1194\/jlr.R076315 (2017).","DOI":"10.1194\/jlr.R076315"},{"key":"40438_CR26","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1172\/jci96429","volume":"128","author":"F Liao","year":"2018","unstructured":"Liao, F. et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. The Journal of Clinical Investigation 128, 2144\u20132155, https:\/\/doi.org\/10.1172\/jci96429 (2018).","journal-title":"The Journal of Clinical Investigation"},{"key":"40438_CR27","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1172\/JCI120414","volume":"128","author":"DR Borchelt","year":"2018","unstructured":"Borchelt, D. R. Targeting the accomplice to thwart the culprit: a new target for the prevention of amyloid deposition. J Clin Invest 128, 1734\u20131736, https:\/\/doi.org\/10.1172\/JCI120414 (2018).","journal-title":"J Clin Invest"},{"key":"40438_CR28","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1434398100","volume":"100","author":"FM Harris","year":"2003","unstructured":"Harris, F. M. et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer\u2019s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 100, 10966\u201310971, https:\/\/doi.org\/10.1073\/pnas.1434398100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"40438_CR29","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1073\/pnas.151254698","volume":"98","author":"Y Huang","year":"2001","unstructured":"Huang, Y. et al. Apolipoprotein E fragments present in Alzheimer\u2019s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proceedings of the National Academy of Sciences of the United States of America 98, 8838\u20138843, https:\/\/doi.org\/10.1073\/pnas.151254698 (2001).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"40438_CR30","doi-asserted-by":"publisher","first-page":"e61498","DOI":"10.1371\/journal.pone.0061498","volume":"8","author":"M Wang","year":"2013","unstructured":"Wang, M. & Turko, I. V. Mass Spectrometry Quantification Revealed Accumulation of C-Terminal Fragment of Apolipoprotein E in the Alzheimer\u2019s Frontal Cortex. PloS one 8, e61498, https:\/\/doi.org\/10.1371\/journal.pone.0061498 (2013).","journal-title":"PloS one"},{"key":"40438_CR31","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1471-4159.2005.03295.x","volume":"94","author":"S Wellnitz","year":"2005","unstructured":"Wellnitz, S. et al. A 13\u2009kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers. Journal of Neurochemistry 94, 1351\u20131360, https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03295.x (2005).","journal-title":"Journal of Neurochemistry"},{"key":"40438_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-017-0280-8","volume":"9","author":"H-Y Wang","year":"2017","unstructured":"Wang, H.-Y. et al. Increased A\u03b2(42)-\u03b17-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer\u2019s disease pathogenesis. Alzheimer\u2019s Research & Therapy 9, 54, https:\/\/doi.org\/10.1186\/s13195-017-0280-8 (2017).","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"40438_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"A Altmann","year":"2014","unstructured":"Altmann, A., Tian, L., Henderson, V. W. & Greicius, M. D., Alzheimer\u2019s Disease Neuroimaging Initiative, I. Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of Neurology 75, 563\u2013573, https:\/\/doi.org\/10.1002\/ana.24135 (2014).","journal-title":"Annals of Neurology"},{"key":"40438_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000446283","volume":"16","author":"A Savioz","year":"2016","unstructured":"Savioz, A. et al. A Study of Abeta Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer\u2019s Disease Compared to Aged Controls. Neuro-degenerative diseases 16, 398\u2013406, https:\/\/doi.org\/10.1159\/000446283 (2016).","journal-title":"Neuro-degenerative diseases"},{"key":"40438_CR35","doi-asserted-by":"publisher","first-page":"14726","DOI":"10.1038\/ncomms14726","volume":"8","author":"O Klementieva","year":"2017","unstructured":"Klementieva, O. et al. Pre-plaque conformational changes in Alzheimer\u2019s disease-linked A\u03b2 and APP. Nature. Communications 8, 14726, https:\/\/doi.org\/10.1038\/ncomms14726 (2017).","journal-title":"Communications"},{"key":"40438_CR36","unstructured":"ALZFORUM. A\u03b2 Oligomers Purified from Human Brain.\u00a0Series - 2016 Zilkha Symposium on Alzheimer Disease & Related Disorders: https:\/\/www.alzforum.org\/news\/research-news\/av-oligomers-purified-human-brain (2016)."},{"key":"40438_CR37","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","volume":"267","author":"H Mori","year":"1992","unstructured":"Mori, H., Takio, K., Ogawara, M. & Selkoe, D. J. Mass spectrometry of purified amyloid beta protein in Alzheimer\u2019s disease. Journal of Biological Chemistry 267, 17082\u201317086 (1992).","journal-title":"Journal of Biological Chemistry"},{"key":"40438_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature11060","volume":"485","author":"JM Nussbaum","year":"2012","unstructured":"Nussbaum, J. M. et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-\u03b2. Nature 485, 651, https:\/\/doi.org\/10.1038\/nature11060 (2012).","journal-title":"Nature"},{"key":"40438_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10422-x","volume":"7","author":"NC Wildburger","year":"2017","unstructured":"Wildburger, N. C. et al. Diversity of Amyloid-beta Proteoforms in the Alzheimer\u2019s Disease Brain. Sci Rep 7, 9520, https:\/\/doi.org\/10.1038\/s41598-017-10422-x (2017).","journal-title":"Sci Rep"},{"key":"40438_CR40","unstructured":"Carter, D. B. In Alzheimer\u2019s Disease: Cellular and Molecular Aspects of Amyloid \u03b2 (eds J. Robin Harris & Falk Fahrenholz) 255\u2013272 (Springer US, 2005)."},{"key":"40438_CR41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/jnen\/60.4.342","volume":"60","author":"HS Cho","year":"2001","unstructured":"Cho, H. S., Hyman, B. T., Greenberg, S. M. & Rebeck, G. W. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. Journal of neuropathology and experimental neurology 60, 342\u2013349 (2001).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"40438_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/srep30654","volume":"6","author":"I Dafnis","year":"2016","unstructured":"Dafnis, I. et al. The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific. Sci Rep 6, 30654, https:\/\/doi.org\/10.1038\/srep30654 (2016).","journal-title":"Sci Rep"},{"key":"40438_CR43","unstructured":"ALZFORUM. Does ApoE Fragmentation Drive Pathology?, https:\/\/www.alzforum.org\/news\/conference-coverage\/keystone-does-apoe-fragmentation drive pathology (2012)."},{"key":"40438_CR44","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter, W. J. et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proceedings of the National Academy of Sciences 90, 8098\u20138102 (1993).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"40438_CR45","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","volume":"288","author":"LM Tai","year":"2013","unstructured":"Tai, L. M. et al. Levels of Soluble Apolipoprotein E\/Amyloid-\u03b2 (A\u03b2) Complex Are Reduced and Oligomeric A\u03b2 Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples. Journal of Biological Chemistry 288, 5914\u20135926, https:\/\/doi.org\/10.1074\/jbc.M112.442103 (2013).","journal-title":"Journal of Biological Chemistry"},{"key":"40438_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbalip.2011.11.005","volume":"1821","author":"MJ LaDu","year":"2012","unstructured":"LaDu, M. J. et al. Preferential interactions between ApoE-containing lipoproteins and A\u03b2 revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821, 295\u2013302, https:\/\/doi.org\/10.1016\/j.bbalip.2011.11.005 (2012).","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"key":"40438_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1326-9-2","volume":"9","author":"LM Tai","year":"2014","unstructured":"Tai, L. M. et al. Soluble apoE\/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener 9, 2, https:\/\/doi.org\/10.1186\/1750-1326-9-2 (2014).","journal-title":"Mol Neurodegener"},{"key":"40438_CR48","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1212\/wnl.0000000000000431","volume":"82","author":"EC Mormino","year":"2014","unstructured":"Mormino, E. C. et al. Amyloid and APOE \u03b54 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82, 1760\u20131767, https:\/\/doi.org\/10.1212\/wnl.0000000000000431 (2014).","journal-title":"Neurology"},{"key":"40438_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17352\/jnnsd.000011","volume":"3","author":"JW Gause","year":"2017","unstructured":"Gause, J. W., Day, R. J., Caraway, C. A., Poon, W. W. & Rohn, T. T. Evaluation of Apolipoprotein E Fragmentation as a Biomarker for Alzheimer\u2019s Disease. Journal of Neurology and Neurological Disorders 3, 1\u20137 (2017).","journal-title":"Journal of Neurology and Neurological Disorders"},{"issue":"203","key":"40438_CR50","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.neurobiolaging.2010.07.023","volume":"33","author":"S Lagadec","year":"2012","unstructured":"Lagadec, S. et al. Early temporal short-term memory deficits in double transgenic APP\/PS1 mice. Neurobiol Aging 33(203), e201\u2013211, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.07.023 (2012).","journal-title":"Neurobiol Aging"},{"key":"40438_CR51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-2275(20)43176-1","volume":"31","author":"JE Hixson","year":"1990","unstructured":"Hixson, J. E. & Vernier, D. T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Journal of lipid research 31, 545\u2013548 (1990).","journal-title":"Journal of lipid research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40438-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:21:43Z","timestamp":1671261703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40438-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40438"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40438-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"31 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3989"}}